Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells

Nikolai Gorbunov, G. Petrovski, Narasimman Gurusamy, Diptarka Ray, Do Han Kim, Dipak K. Das

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The major problem in stem cell therapy includes viability and engraftment efficacy of stem cells after transplantation. Indeed, the vast majority of host-transfused cells do not survive beyond 24-72 hrs. To increase the survival and engraftment of implanted cardiac stem cells in the host, we developed a technique of treating these cells with resveratrol, and tested it in a rat model of left anterior descending (LAD) occlusion. Multi-potent clonogenic cardiac stem cells isolated from rat heart and stably transfected with EGFP were pre-treated with 2.5 μM resveratrol for 60 min. Rats were anaesthetized, hearts opened and the LAD occluded to induce heart attack. One week later, the cardiac reduced environment was confirmed in resveratrol treated rat hearts by the enhanced expression of nuclear factor-E2-related factor-2 (Nrf2) and redox effector factor-1 (Ref-1). M-mode echocardiography after stem cell therapy, showed improvement in cardiac function (left ventricular ejection fraction, fractional shortening and cardiac output) in both, the treated and control group after 7 days, but only resveratrol-modified stem cell group revealed improvement in cardiac function at the end of 1, 2 and 4 months time. The improvement of cardiac function was accompanied by enhanced stem cell survival and engraftment as demonstrated by the expression of cell proliferation marker Ki67 and differentiation of stem cells towards the regeneration of the myocardium as demonstrated by the expression of EGFP up to 4 months after LAD occlusion in the resveratrol-treated stem cell group. Expression of stromal cell-derived factor and myosin conclusively demonstrated homing of stem cells in the infarcted myocardium, its regeneration leading to improvement of cardiac function.

Original languageEnglish
Pages (from-to)174-184
Number of pages11
JournalJournal of Cellular and Molecular Medicine
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Regeneration
Myocardium
Stem Cells
Cell- and Tissue-Based Therapy
NF-E2-Related Factor 2
resveratrol
Differentiation Antigens
Stem Cell Transplantation
Myosins
Stromal Cells
Cardiac Output
Stroke Volume
Oxidation-Reduction
Echocardiography
Cell Survival
Myocardial Infarction
Cell Proliferation
Control Groups

Keywords

  • Cardiac stem cells
  • Heart
  • Ischaemia
  • NFκB
  • Nrf2
  • Redox
  • Ref-1
  • Resveratrol
  • SDF

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells. / Gorbunov, Nikolai; Petrovski, G.; Gurusamy, Narasimman; Ray, Diptarka; Kim, Do Han; Das, Dipak K.

In: Journal of Cellular and Molecular Medicine, Vol. 16, No. 1, 01.2012, p. 174-184.

Research output: Contribution to journalArticle

Gorbunov, Nikolai ; Petrovski, G. ; Gurusamy, Narasimman ; Ray, Diptarka ; Kim, Do Han ; Das, Dipak K. / Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells. In: Journal of Cellular and Molecular Medicine. 2012 ; Vol. 16, No. 1. pp. 174-184.
@article{32d729a8751e468eb124d5731405c9a2,
title = "Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells",
abstract = "The major problem in stem cell therapy includes viability and engraftment efficacy of stem cells after transplantation. Indeed, the vast majority of host-transfused cells do not survive beyond 24-72 hrs. To increase the survival and engraftment of implanted cardiac stem cells in the host, we developed a technique of treating these cells with resveratrol, and tested it in a rat model of left anterior descending (LAD) occlusion. Multi-potent clonogenic cardiac stem cells isolated from rat heart and stably transfected with EGFP were pre-treated with 2.5 μM resveratrol for 60 min. Rats were anaesthetized, hearts opened and the LAD occluded to induce heart attack. One week later, the cardiac reduced environment was confirmed in resveratrol treated rat hearts by the enhanced expression of nuclear factor-E2-related factor-2 (Nrf2) and redox effector factor-1 (Ref-1). M-mode echocardiography after stem cell therapy, showed improvement in cardiac function (left ventricular ejection fraction, fractional shortening and cardiac output) in both, the treated and control group after 7 days, but only resveratrol-modified stem cell group revealed improvement in cardiac function at the end of 1, 2 and 4 months time. The improvement of cardiac function was accompanied by enhanced stem cell survival and engraftment as demonstrated by the expression of cell proliferation marker Ki67 and differentiation of stem cells towards the regeneration of the myocardium as demonstrated by the expression of EGFP up to 4 months after LAD occlusion in the resveratrol-treated stem cell group. Expression of stromal cell-derived factor and myosin conclusively demonstrated homing of stem cells in the infarcted myocardium, its regeneration leading to improvement of cardiac function.",
keywords = "Cardiac stem cells, Heart, Ischaemia, NFκB, Nrf2, Redox, Ref-1, Resveratrol, SDF",
author = "Nikolai Gorbunov and G. Petrovski and Narasimman Gurusamy and Diptarka Ray and Kim, {Do Han} and Das, {Dipak K.}",
year = "2012",
month = "1",
doi = "10.1111/j.1582-4934.2011.01281.x",
language = "English",
volume = "16",
pages = "174--184",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells

AU - Gorbunov, Nikolai

AU - Petrovski, G.

AU - Gurusamy, Narasimman

AU - Ray, Diptarka

AU - Kim, Do Han

AU - Das, Dipak K.

PY - 2012/1

Y1 - 2012/1

N2 - The major problem in stem cell therapy includes viability and engraftment efficacy of stem cells after transplantation. Indeed, the vast majority of host-transfused cells do not survive beyond 24-72 hrs. To increase the survival and engraftment of implanted cardiac stem cells in the host, we developed a technique of treating these cells with resveratrol, and tested it in a rat model of left anterior descending (LAD) occlusion. Multi-potent clonogenic cardiac stem cells isolated from rat heart and stably transfected with EGFP were pre-treated with 2.5 μM resveratrol for 60 min. Rats were anaesthetized, hearts opened and the LAD occluded to induce heart attack. One week later, the cardiac reduced environment was confirmed in resveratrol treated rat hearts by the enhanced expression of nuclear factor-E2-related factor-2 (Nrf2) and redox effector factor-1 (Ref-1). M-mode echocardiography after stem cell therapy, showed improvement in cardiac function (left ventricular ejection fraction, fractional shortening and cardiac output) in both, the treated and control group after 7 days, but only resveratrol-modified stem cell group revealed improvement in cardiac function at the end of 1, 2 and 4 months time. The improvement of cardiac function was accompanied by enhanced stem cell survival and engraftment as demonstrated by the expression of cell proliferation marker Ki67 and differentiation of stem cells towards the regeneration of the myocardium as demonstrated by the expression of EGFP up to 4 months after LAD occlusion in the resveratrol-treated stem cell group. Expression of stromal cell-derived factor and myosin conclusively demonstrated homing of stem cells in the infarcted myocardium, its regeneration leading to improvement of cardiac function.

AB - The major problem in stem cell therapy includes viability and engraftment efficacy of stem cells after transplantation. Indeed, the vast majority of host-transfused cells do not survive beyond 24-72 hrs. To increase the survival and engraftment of implanted cardiac stem cells in the host, we developed a technique of treating these cells with resveratrol, and tested it in a rat model of left anterior descending (LAD) occlusion. Multi-potent clonogenic cardiac stem cells isolated from rat heart and stably transfected with EGFP were pre-treated with 2.5 μM resveratrol for 60 min. Rats were anaesthetized, hearts opened and the LAD occluded to induce heart attack. One week later, the cardiac reduced environment was confirmed in resveratrol treated rat hearts by the enhanced expression of nuclear factor-E2-related factor-2 (Nrf2) and redox effector factor-1 (Ref-1). M-mode echocardiography after stem cell therapy, showed improvement in cardiac function (left ventricular ejection fraction, fractional shortening and cardiac output) in both, the treated and control group after 7 days, but only resveratrol-modified stem cell group revealed improvement in cardiac function at the end of 1, 2 and 4 months time. The improvement of cardiac function was accompanied by enhanced stem cell survival and engraftment as demonstrated by the expression of cell proliferation marker Ki67 and differentiation of stem cells towards the regeneration of the myocardium as demonstrated by the expression of EGFP up to 4 months after LAD occlusion in the resveratrol-treated stem cell group. Expression of stromal cell-derived factor and myosin conclusively demonstrated homing of stem cells in the infarcted myocardium, its regeneration leading to improvement of cardiac function.

KW - Cardiac stem cells

KW - Heart

KW - Ischaemia

KW - NFκB

KW - Nrf2

KW - Redox

KW - Ref-1

KW - Resveratrol

KW - SDF

UR - http://www.scopus.com/inward/record.url?scp=84855173613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855173613&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2011.01281.x

DO - 10.1111/j.1582-4934.2011.01281.x

M3 - Article

VL - 16

SP - 174

EP - 184

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 1

ER -